Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2017-11-30
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of niclosamide when given together
with enzalutamide in treating patients with castration resistant prostate cancer that has
spread from the primary site to other places in the body. Androgens such as testosterone can
cause the growth of prostate cancer cells. Drugs like enzalutamide block androgens from
driving tumor growth; however, when androgen receptor splice variants are present, these
drugs may not be effective. Niclosamide may decrease the amount of androgen receptor splice
variant present within tumor cells, thus promoting the anti-tumor effects of enzalutamide.
Giving niclosamide together with enzalutamide may be a better treatment for prostate cancer.